Equity Profile

IONS

Ionis Pharmaceuticals, Inc.

Health CareBiotechnology$12.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well Ionis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future research and development.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for patients with serious diseases. Operating in the health care sector, Ionis specializes in RNA-targeted drug discovery and development, which is a significant theme in modern medicine as it aims to address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1 2026, Ionis reported an EPS of -$0.56, outperforming estimates by 37.36%. The stock reacted positively, gaining 4.25% the following day.

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to cost management and operational efficiency.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Ionis's upcoming earnings, especially given its history of beating EPS estimates. However, uncertainty remains regarding revenue growth and overall market conditions.

Bull Case

If Ionis can deliver strong EPS and show significant revenue growth, it could reinforce investor confidence and lead to a substantial stock price increase.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in determining whether Ionis continues its trend of beating estimates, which could significantly influence investor sentiment.

How is the revenue growth expected to trend this quarter?

Understanding revenue growth will provide insights into the company's market performance and its ability to sustain operations and fund future projects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Ionis's recent advancements in its drug pipeline, which could lead to better-than-expected revenue growth this quarter.

Supporting Evidence

Ionis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Recent insider selling may indicate a strategic shift rather than a lack of confidence in the company's future.

The options market is pricing in a larger move than historically realized, suggesting that traders expect significant news.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can maintain its positive momentum from previous quarters, especially in light of recent performance.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.70 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by around 1.92%, confirming the company's positive trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential decline of around 5.29%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of pipeline candidates.
2Details on cost management strategies and their impact on profitability.
3Insights into partnerships and collaborations for drug development.
4Guidance on expected revenue growth for the upcoming quarters.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well Ionis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future research and development.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1 2026, Ionis reported an EPS of -$0.56, outperforming estimates by 37.36%. The stock reacted positively, gaining 4.25% the following day.

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to cost management and operational efficiency.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Bull Case

If Ionis can deliver strong EPS and show significant revenue growth, it could reinforce investor confidence and lead to a substantial stock price increase.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in determining whether Ionis continues its trend of beating estimates, which could significantly influence investor sentiment.

How is the revenue growth expected to trend this quarter?

Understanding revenue growth will provide insights into the company's market performance and its ability to sustain operations and fund future projects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Ionis's recent advancements in its drug pipeline, which could lead to better-than-expected revenue growth this quarter.

Supporting Evidence

Ionis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Recent insider selling may indicate a strategic shift rather than a lack of confidence in the company's future.

The options market is pricing in a larger move than historically realized, suggesting that traders expect significant news.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can maintain its positive momentum from previous quarters, especially in light of recent performance.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.70 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by around 1.92%, confirming the company's positive trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential decline of around 5.29%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of pipeline candidates.
2Details on cost management strategies and their impact on profitability.
3Insights into partnerships and collaborations for drug development.
4Guidance on expected revenue growth for the upcoming quarters.
5Management's outlook on market conditions and competitive landscape.